Nanomaterials: Versatile Drug Carriers for Nanomedicine
287
is essential for the fundamental research that is needed to be carried out to address
them for the successful and efficient application of these technologies.
Besides, a significant challenge faced by the new generation in this field is its
highly interdisciplinary nature, the best course will be to train an of truly interdisciplinary investigators having firm multidisciplinary grounding. The US FDA has
approved some nanoparticle-based products, and several others are currently under
development process and clinical assessment. In summary, although nanomedicine
is still in its infancy, these practical applications demonstrate its enormous potential.
References
1. Park K (2013) Facing the truth about nanotechnology in drug delivery. ACS Nano 7:7442–
7447
2. Edwards PP, Thomas JM (2007) Gold in a metallic divided state—from faraday to present-day
nanoscience. Angew Chemie Int Ed 46:5480–5486
3. Wissing SA, Kayser O, Müller RH (2004) Solid lipid nanoparticles for parenteral drug
delivery. Adv Drug Deliv Rev 56:1257–1272
4. Pachón LD, Rothenberg G (2008) Transition-metal nanoparticles: synthesis, stability and the
leaching issue. Appl Organomet Chem 22:288–299
5. Hoffman AS (2008) The origins and evolution of “controlled” drug delivery systems. J Control
release 132:153–163
6. Zhang Y, Chan HF, Leong KW (2013) Advanced materials and processing for drug delivery:
the past and the future. Adv Drug Deliv Rev 65:104–120
7. Lane N, Kalil T (2005) The national nanotechnology initiative: present at the creation. Issues
Sci Technol 21:49–54
8. Jong JW, Borm PJA (2008) Drug delivery and nanoparticles: applications and hazards. Int J
Nanomed 3:133–149. https://doi.org/10.2147/ijn.s596
9. Webster DM, Sundaram P, Byrne ME (2013) Injectable nanomaterials for drug delivery:
carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm 84:1–20
10. Chakarvarty G, Seth N, Sharma V (2013) Nanoparticles and nanotechnology: clinical,
toxicological, social, regulatory and other aspects of nanotechnology. J Drug Deliv Ther
3:138–141
11. Sahoo SK, Parveen S, Panda JJ (2007) The present and future of nanotechnology in human
health care. Nanomed Nanotechnol Biol Med 3:20–31. https://doi.org/10.1016/j.nano.2006.
11.008
12. Jahangirian H, Lemraski EG, Webster TJ, Rafiee-Moghaddam R, Abdollahi Y (2017) A review
of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine.
Int J Nanomedicine 12:2957
13. Irving B (2007) Nanoparticle drug delivery systems. Innov Pharm Technol 58–62. https://doi.
org/10.1385/1-59259-427-1:117
14. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, DiazTorres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS (2018) Nano based drug
delivery systems: recent developments and future prospects. J Nanobiotechnology 16:1–33.
https://doi.org/10.1186/s12951-018-0392-8
15. Calvo P, Remuñan-López C, Vila-Jato JL, Alonso MJ (1997) Chitosan and chitosan/ethylene
oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and
vaccines. Pharm Res 14:1431–1436. https://doi.org/10.1023/A:1012128907225
16. Chen Y, McCulloch R, Gray B (1994) Synthesis of albumin-dextran sulfate microspheres
possessing favourable loading and release characteristics for the anticancer drug doxorubicin.
J Control release 31:49–54
287
is essential for the fundamental research that is needed to be carried out to address
them for the successful and efficient application of these technologies.
Besides, a significant challenge faced by the new generation in this field is its
highly interdisciplinary nature, the best course will be to train an of truly interdisciplinary investigators having firm multidisciplinary grounding. The US FDA has
approved some nanoparticle-based products, and several others are currently under
development process and clinical assessment. In summary, although nanomedicine
is still in its infancy, these practical applications demonstrate its enormous potential.
References
1. Park K (2013) Facing the truth about nanotechnology in drug delivery. ACS Nano 7:7442–
7447
2. Edwards PP, Thomas JM (2007) Gold in a metallic divided state—from faraday to present-day
nanoscience. Angew Chemie Int Ed 46:5480–5486
3. Wissing SA, Kayser O, Müller RH (2004) Solid lipid nanoparticles for parenteral drug
delivery. Adv Drug Deliv Rev 56:1257–1272
4. Pachón LD, Rothenberg G (2008) Transition-metal nanoparticles: synthesis, stability and the
leaching issue. Appl Organomet Chem 22:288–299
5. Hoffman AS (2008) The origins and evolution of “controlled” drug delivery systems. J Control
release 132:153–163
6. Zhang Y, Chan HF, Leong KW (2013) Advanced materials and processing for drug delivery:
the past and the future. Adv Drug Deliv Rev 65:104–120
7. Lane N, Kalil T (2005) The national nanotechnology initiative: present at the creation. Issues
Sci Technol 21:49–54
8. Jong JW, Borm PJA (2008) Drug delivery and nanoparticles: applications and hazards. Int J
Nanomed 3:133–149. https://doi.org/10.2147/ijn.s596
9. Webster DM, Sundaram P, Byrne ME (2013) Injectable nanomaterials for drug delivery:
carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm 84:1–20
10. Chakarvarty G, Seth N, Sharma V (2013) Nanoparticles and nanotechnology: clinical,
toxicological, social, regulatory and other aspects of nanotechnology. J Drug Deliv Ther
3:138–141
11. Sahoo SK, Parveen S, Panda JJ (2007) The present and future of nanotechnology in human
health care. Nanomed Nanotechnol Biol Med 3:20–31. https://doi.org/10.1016/j.nano.2006.
11.008
12. Jahangirian H, Lemraski EG, Webster TJ, Rafiee-Moghaddam R, Abdollahi Y (2017) A review
of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine.
Int J Nanomedicine 12:2957
13. Irving B (2007) Nanoparticle drug delivery systems. Innov Pharm Technol 58–62. https://doi.
org/10.1385/1-59259-427-1:117
14. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, DiazTorres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS (2018) Nano based drug
delivery systems: recent developments and future prospects. J Nanobiotechnology 16:1–33.
https://doi.org/10.1186/s12951-018-0392-8
15. Calvo P, Remuñan-López C, Vila-Jato JL, Alonso MJ (1997) Chitosan and chitosan/ethylene
oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and
vaccines. Pharm Res 14:1431–1436. https://doi.org/10.1023/A:1012128907225
16. Chen Y, McCulloch R, Gray B (1994) Synthesis of albumin-dextran sulfate microspheres
possessing favourable loading and release characteristics for the anticancer drug doxorubicin.
J Control release 31:49–54